King Abdulaziz Medical City

Running trials

• Recruiting

  Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

  NCT06823466· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Source

• Active, not recruiting

  Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)

  NCT07579390· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

  NCT05361434· Source

• Withdrawn

  A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

  NCT04264806· Phase 2· Source

• Completed

  A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  NCT03587116· Phase 3· Source

Trial sites

• King Abdulaziz Medical City2 trials
• King Abdulaziz Medical City5 trials
• King Abdulaziz Medical City, King Abdullah International Medical Research Center1 trial
• King Abdulaziz Medical City- Riyadh1 trial